Cerevance

Cerevance is pioneering a new approach to CNS drug discovery by utilizing its proprietary NETSseq platform to analyze human post-mortem brain tissue, enabling the identification of novel, disease-relevant targets with high specificity. The company's lead asset, solengepras, a GPR6 inverse agonist, has demonstrated positive Phase 2 results in Parkinson's disease and is now in a pivotal Phase 3 trial, positioning it as a potential first-in-class, non-dopaminergic therapy. With a deep pipeline targeting neurodegenerative, psychiatric, and metabolic disorders, and strategic collaborations with major pharmaceutical companies, Cerevance is building a robust portfolio aimed at addressing significant unmet needs in brain health.

NETSseq (Nuclear Enriched Transcript Sort sequencing) - a proprietary platform that analyzes gene expression in specific cell types from human post-mortem brain tissue to identify novel, disease-relevant drug targets.

In Parkinson's disease, Cerevance competes with both established dopamine-based therapies and other companies developing non-dopaminergic approaches (e.g., adenosine A2A antagonists, glutamate modulators). Its human-centric NETSseq platform provides a key differentiation in target discovery, but it competes with other genomics and data-driven neuroscience platforms from both biotech and large pharma in identifying the next generation of CNS targets.